913258-31-8

Basic information

• Product Name: methyl (Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
• Synonyms: methyl (Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
• CAS NO: 913258-31-8
• Molecular Weight: 404.547
• Mol File: 913258-31-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl (Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate(913258-31-8)
• EPA Substance Registry System: methyl (Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate(913258-31-8)

Safety Data

• Hazardous Substances Data: 913258-31-8(Hazardous Substances Data)

Upstream product

• 41639-83-2 latanoprost acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 67-56-1 methanol 
• 913258-25-0 2,2-bis(hydroxymethyl)propyl-(Z)-7-[(1R,2R,3R,5S)-2-[(3S)-3-triethylsilyloxy-5-phenyl-1-(phenylsulfonyl)pentyl]-3,5-bis(triethylsilyloxy)cyclopentyl]hept-5-enoate 
• 930118-48-2 methyl (Z)-7-[(1R,2R,3R,5S)-2-((3S)-3-triethylsilyloxy-5-phenyl-1-(phenylsulfonyl)pentyl)-3,5-bis(triethylsilyloxy)cyclopentyl]hept-5-enoate 
• 913258-20-5 (S)-4-phenyl-1-iodo-2-(triethylsiloxy)butane 
• 913258-17-0 1-<(Z)-6-{(1R,2R,3R,5S)-2-[(phenylsulfonyl)methyl]-3,5-bis(triethylsiloxy)cyclopentyl}hex-4-enyl>-4-methyl-2,6,7-trioxabicyclo[2.2.2]octane 

Downstream Products

• 145773-22-4 isopropyl (E)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate 
• 41639-83-2 latanoprost acid 

Relevant articles and documents

COMBINATION THERAPY

Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2α DERIVATIVES

Invention relates to the process for preparation of 13,14-dihydro-PGF2α derivatives of R or S configuration at carbon atom in omega chain substituted by hydroxyl, represented by formula (I), wherein the meaning of substituents is defined in the description. Compounds (I) are valuable biologically active substances or intermediates thereof. The invention especially relates to the process for preparation of 13,14-dihydro-15(R)-17-substituted-18,19,20-trinor-PGF2α, ie. latanoprost.